Skip to main content
. 2016 May 9;7(24):36971–36987. doi: 10.18632/oncotarget.9235

Figure 2. Cleaved-Par-4 protein is stabilized upon cisplatin treatment.

Figure 2

A. Schematic of cl-Par-4 transgene and its domains for the production of stable clones, used throughout the manuscript. B. Ovarian and endometrial cancer cells were stably transduced with cl-Par-4-myc plasmid using lentiviral particles. C-D. Cl-Par-4 cancer cell lines were treated with 10-20μM Cisplatin for 24h. E. Ishikawa Cl-Par-4 cancer cell lines were treated with 20μM Cisplatin for 2h, 6h or 24h. The protein level of cl-Par-4-myc was determined in treated cells using western blot analysis. β-Actin or GAPDH were used as a loading control. Results shown are representative of three independent experiments. Results are mean ± S.E.M. of three independent experiments. *=P<0.05; **=P<0.01 and ***=P<0.001 when compared with corresponding mock-treated cells.